Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsProvidence infusion site-of-care Prior Auth | Open…
    Ask Trek AI about this page
    CurrentProvidence Health PlanPolicy ORPTCOTH030

    Miscellaneous Products Infusion Therapy Site-of-Care Prior Authorization

    Customize your policy alerts

    Sign up for Providence Health Plan Policy ORPTCOTH030 alerts

    Get alerted when Policy ORPTCOTH030 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs prior authorization and site-of-care requirements for administration of specified infusion medications for Providence Health Plan commercial members aged 13 and older, defining approved and unapproved infusion settings and criteria for allowing administration in unapproved hospital outpatient infusion centers.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products Infusion Therapy Site-of-Care Prior Authorization
    Policy CodePolicy ORPTCOTH030
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when required and document the specific HCPCS/J/Q code and any applicable new-start dose exception on requests.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    13+minimum member age covered
    Up to 1 yrinitial and reauthorization coverage duration
    First dosefirst-dose waiver
    ~80+listed HCPCS/J/Q codes
    1–6new start dose exceptions

    Coverage Criteria and Medical Necessity

    Medical necessity exceptions for unapproved site

    Unapproved hospital-based outpatient infusion center may be considered medically necessary if ANY of the following are met:

    Unapproved site allowed: Patient has concomitant conditions or clinical history increasing risk of infusion reactions or drug-specific adverse events

    Examples include recent documented severe adverse drug reactions or anaphylaxis; concomitant complex medical conditions (e.g., antibodies increasing infusion reaction risk, severely compromised cardiac or respiratory function); use of multiple concurrent therapies requiring higher level care (for example cytotoxic chemotherapy or CAR‑T administered over the same treatment period); chronic vascular access complications requiring hospital-based interventions/equipment; mental health or cognitive changes requiring higher level care

    Unapproved site allowed - appropriateness: Unapproved hospital-based infusion center is more appropriate because home infusion services are not an option or the home is ineligible/unfit/unsafe for home infusion

    Home ineligibility examples include the member's home being outside the infusion provider's service area, or upon inspection the home is considered unfit or unsafe for home infusion services

    Initial dose exceptions

    Site-of-care criteria shall be waived for the administration of the first dose for all drugs; additional limited doses for certain drugs may be allowed to assess tolerability in higher level care:

    First dose waiver: First dose administration at an unapproved site is permitted to allow arrangement of an approved site of care

    Select drugs (for example certain enzyme replacement therapies and oncology immunotherapies) may be permitted additional doses at a non-approved site to assess tolerability; the number of additional doses is established based on the drug safety profile and manufacturer recommendations and is listed in the HCPCS drug table

    Position statement — alternate-site infusion

    Policy position and clinical rationale for alternate-site infusion

    Position Statement: Home and alternate-site infusion is cost-effective, clinically comparable to facility care, and preferred by many patients; site-of-care determinations should favor home or infusion suite when clinically appropriate

    Supports alternate-site infusion as cost-effective with similar clinical outcomes and high patient preference; individual product coverage and site exceptions continue to be reviewed per medical necessity and the infused medication list is subject to change

    The policy specifies Exclusion Criteria: N/A. No specific exclusions are listed in this segment of the policy.

    There are no explicit product exclusions noted in this portion of the document; the infused medication list is subject to change. Individual medications and any future exclusions will be handled through updates to the policy and reviewed on a case-by-case basis.

    Administration in an unapproved hospital outpatient infusion setting is considered not medically necessary when an approved site of care is available and the unapproved setting is determined to be no longer medically necessary. Use of an unapproved hospital outpatient infusion center should therefore be limited to circumstances meeting the policy's medical necessity exceptions or when an approved site is unavailable.

    This segment does not enumerate additional explicit not medically necessary conditions beyond the general denial trigger; however, exceptions to site-of-care determinations are reviewed individually and denials may occur when exception criteria or supporting documentation are not provided.

    HCPCS/J/Q Codes and Dose Exceptions

    Site-of-care infusion HCPCS codes and new-start dose exceptionsHCPCS
    J0791Adakveo (crizanlizumab) — New Start Dose Exceptions = 1
    J1931Aldurazyme (laronidase)
    J1552Alyglo (immune globulin) — New Start Dose Exceptions = 1
    J1426Amondys 45 (casimersen) — New Start Dose Exceptions = 1
    J0225Amvuttra (vutrisiran) — New Start Dose Exceptions = 1
    J0256Aralast NP / Prolastin-C / Zemaira (alpha-1 proteinase inhibitor) — New Start Dose Exceptions = 1
    J0881Aranesp (darbepoetin alfa) — New Start Dose Exceptions = 1
    J1554Asceniv (immune globulin) — New Start Dose Exceptions = 1
    Q5121Avsola (infliximab-axxq) — New Start Dose Exceptions = 1
    J9023Bavencio (avelumab)
    1–10 of 34
    1/4
    Listed HCPCS/J/Q CodesHCPCSCovered
    J1305Evinacumab
    J1428Evkeeza / Exondys 51 / Eteplirsen (entries present)
    J0180Fabrazyme / agalsidase beta
    J9395Faslodex / fulvestrant
    J9394Fresenius Kabi / fulvestrant
    J1569505(b)(2) Gammagard
    J1561Gammagard ERC / Gammaked / immune globulin
    J1557Gamunex-C / Gammaplex / immune globulin
    J0223Givlaari / givosiran
    J0257Glassia / alpha-1 proteinase inhibitor
    1–10 of 77
    1/8
    Dose exception windows — examples
    Example - 4 doses within 60 daysDarzalex (daratumumab) — New Start Dose Exceptions = 4 doses within 60 days
    Example - 6 doses within 90 daysElaprase (idursulfase) / Elelyso (taliglucerase alfa) — New Start Dose Exceptions = 6 doses within 90 days
    Example - 4 doses within 60 days (alternative)Faslodex (fulvestrant) — New Start Dose Exceptions = 4 doses within 60 days
    New start dose exceptions — per-product numeric allowances
    Single-dose allowanceMultiple products (e.g., J1305 Evkeeza, J1428 Exondys 51, J1569 Gammagard) — New Start Dose Exceptions = 1
    2 doses within 60 days

    Provider Requirements and Authorization Actions

    Prior Authorization

    Prior authorization required when applicable

    Obtain prior authorization for the medication when required; note that authorization decisions for clinical criteria are separate from decisions about use of an unapproved hospital outpatient infusion center.

    Prior Authorization

    PA required for listed HCPCS/J/Q infusion products

    Submit prior authorization requests for the listed HCPCS/J/Q infusion products and include any applicable 'New Start Dose Exceptions' allowance for initial dosing as specified for each product.

    Step Therapy

    First‑dose waiver and arrange transition to approved site

    If an approved site is not yet arranged, the first dose may be administered at an unapproved site to allow time to transition the member to an approved alternative site; additional limited new‑start doses are permitted only as specified per drug.

    Definitions

    Site of Care — definition
    DefinitionThe physical location where the infusion therapy is administered (such as an inpatient hospital, outpatient hospital-based infusion center, standalone infusion center, healthcare provider's office, or home infusion)
    IncludesInpatient hospital, outpatient hospital-based infusion center, standalone infusion center, provider's office, or home infusion
    ContextUsed to determine whether administration must occur at an approved site of care per policy
    Alternative Site of Care — definition
    DefinitionAny outpatient infusion site of care outside of an outpatient hospital-based infusion center (such as provider's office or home infusion service providers)
    ExamplesProvider's office; home infusion service provider; standalone infusion clinic

    Initial Therapy Site-of-Care Exceptions

    Initial therapy allowances

    Initial therapy site-of-care exceptions

    First dose allowed at unapproved site: First dose is permitted at an unapproved site to allow arrangement of an approved site of care

    Certain drugs have additional allowed new-start doses as specified in the HCPCS tables (see drug-specific New Start Dose Exceptions)

    Initial therapy — new start dose exceptions

    Initial authorization may use New Start Dose Exceptions as specified per HCPCS code.

    Initial authorization guidance: Use the HCPCS code-specific 'New Start Dose Exceptions' allowance when requesting initial coverage; document the HCPCS code, drug, dose, and interval consistent with the listed exception (examples include '1', '2 doses within 60 days', '4 doses within 60 days', or '6 doses within 90 days')

    Exact numeric allowances are listed in the HCPCS/drug tables in this policy and should be applied for initial authorizations; clinical eligibility criteria for each drug are addressed in individual drug policies

    Reauthorization and Continuation Requirements

    Reauthorization

    Reauthorization occurs every six months and requires documentation of continued clinical need and consideration of available approved sites for transfer.

    Reauthorization: Documentation of clinical and administration notes from the past six months demonstrating continued need for the unapproved site of careevery 6 months

    Reauthorization decisions will include consideration of transfer to any newly available approved sites of care; approvals may be up to one year per authorization

    Site-of-Care Transition and Step Therapy

    StepRequirement / Action
    1
    Transition to the most affordable medically appropriate site of care when an approved site is available; initial dosing/first‑dose exceptions permitted to allow arrangement of an approved site of care
    StepDetails
    0
    No explicit step‑therapy sequencing, mandatory trial/failure requirements, or ordered therapeutic steps are specified in this policy segment; the policy emphasizes preference for alternate‑site (home/infusion suite) care when clinically appropriate

    Approved and Alternate Sites of Care

    Note

    Administer at approved site when available; first-dose waiver and select exceptions apply

    Specified drugs require administration at an approved site of care when an approved site is available; the policy waives the site-of-care requirement for the first dose and provides select additional New Start Dose Exceptions for certain products.

    • First-dose waiver applies for all drugs to allow arranging an approved site.
    • Select HCPCS-coded products have per-code New Start Dose Exceptions as listed in the policy.
    Note

    Support for home or alternate-site infusion

    Alternate-site infusion (home or the home-infusion provider's suite) is supported as cost‑effective and clinically appropriate for many patients and is preferred when clinically appropriate.

    • Policy states home and alternate-site infusion are cost‑effective and have comparable clinical outcomes.

    Background and Rationale

    Historically, infusion therapy was delivered in outpatient hospital facilities but has increasingly shifted to alternative sites (provider office, stand-alone infusion centers, or patient home) driven by cost-effectiveness and patient preference. The policy supports alternate-site infusion when clinically appropriate and notes studies showing increased home infusion utilization and generally low rates of serious infusion reactions in monitored alternative settings; exceptions to site-of-care determinations are reviewed case-by-case and the infused medication list may guide which products are suitable for non-hospital settings.

    Policy Summary
    PayerProvidence Health Plan
    PolicyMiscellaneous Products Infusion Therapy Site-of-Care Prior Authorization
    Policy CodePolicy ORPTCOTH030
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when required and document the specific HCPCS/J/Q code and any applicable new-start dose exception on requests.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityHCPCS/J/Q Codes and Dose ExceptionsProvider Requirements and Authorization ActionsDefinitionsInitial Therapy Site-of-Care ExceptionsReauthorization and Continuation RequirementsSite-of-Care Transition and Step TherapyApproved and Alternate Sites of CareBackground and Rationale
    Herceptin Hylecta (J9356), Jemperli (J9272), Kadcyla (J9354), many rituximab-related products (J9312/Q5115/Q5123) — New Start Dose Exceptions = 2 doses within 60 days
    4 doses within 60 daysDarzalex (J9145) / Darzalex Faspro (J9144), Faslodex (J9395/J9394), Trodelvy (J9317) — New Start Dose Exceptions = 4 doses within 60 days
    6 doses within 90 daysEnzyme replacement products (e.g., Fabrazyme J0180, Lumizyme J0221, Mepsevii J3397, Kanuma J2840) — New Start Dose Exceptions = 6 doses within 90 days
    Note

    Alternate‑site infusion favored; no mandated step‑therapy

    Preference is for alternate‑site infusion (home or specialty infusion) as a cost‑effective, clinically comparable option; the policy does not impose specific step‑therapy sequencing or mandatory medication failures.

    Documentation Required

    Document clinical need and administration notes for PA and reauthorization

    Include prior authorization (when required) plus clinical and administration notes that document the continued need for the unapproved site; reauthorization requires six‑month clinical/administration documentation and consideration of transfer to available approved sites.

    • Clinical justification for why the unapproved site is necessary (e.g., one of the medical necessity exception criteria)
    • Administration notes from the past six months for reauthorization
    • Documentation of attempts/plan to transfer to an approved site, if applicable
    Billing Rule

    Include HCPCS code and new‑start dose exception on PA

    Reference the specific HCPCS/J/Q code for the infused product on the prior authorization request and document any New Start Dose Exceptions used (e.g., '4 doses within 60 days' or '6 doses within 90 days') consistent with the HCPCS table.

    • Specify HCPCS/J/Q code for the requested product
    • State the new‑start dose allowance being applied (per the listed exception for that code)
    Denial Risk

    Risk of denial for unapproved hospital outpatient infusion

    Claims for administration in an unapproved hospital outpatient infusion setting may be denied when an approved site of care is available and the unapproved setting is not justified by documented medical necessity.

    Denial Risk

    Exceptions reviewed individually; insufficient support may cause denial

    Request site‑of‑care exceptions will be reviewed case‑by‑case; failure to provide documentation that meets the medical‑necessity exception criteria or home‑ineligibility reasons may result in denial.

    • Provide documentation matching one of the unapproved‑site medical necessity criteria (e.g., recent severe adverse reaction, need for hospital‑level equipment, home deemed unsafe or out of service area)
    • If invoking a New Start Dose Exception, document the specific exception and clinical rationale
    ImplicationAlternative sites are considered 'approved' when appropriate and cost-effective per policy
    Approved Site of Care — definition
    DefinitionAlternative sites of care or approved hospital-based infusion centers
    What it meansSites designated by policy as acceptable locations for infusion when available (e.g., home infusion, provider office, approved infusion center)
    Policy useMembers should transfer to approved sites when available unless medical necessity exceptions apply
    Unapproved Site of Care — definition
    DefinitionAny site of care that has been deemed as medically unnecessary, including unapproved hospital-based infusion centers that increase the cost of care compared to approved sites of care
    ExamplesHospital-based outpatient infusion centers considered more costly than available approved alternatives
    ConsequenceAdministration at an unapproved site will be denied when an approved site of care is available and unapproved setting is no longer medically necessary
    HCPCS new-start dose exceptions — numeric allowances by HCPCS code
    Per-HCPCS allowance (single)Many HCPCS codes carry a New Start Dose Exceptions = 1 (examples: J1305, J1428, J1569, J1561)
    Per-HCPCS allowance (2-dose window)Selected codes allow 2 doses within 60 days (examples: J9356 Herceptin Hylecta, J9272 Jemperli, Q5116 Trazimera)
    Per-HCPCS allowance (4-dose window)Selected oncology/immunotherapy codes allow 4 doses within 60 days (examples: J9145 Darzalex, J9144 Darzalex Faspro, J9317 Trodelvy)
    Per-HCPCS allowance (6-dose window)Certain enzyme replacement and similar therapies allow 6 doses within 90 days (examples: J0180 Fabrazyme, J0221 Lumizyme, J2840 Kanuma)